Nemolizumab, sold under the brand name Nemluvio, is a medication for the treatment of prurigo nodularis.[2] It is a monoclonal antibody that blocks the interleukin-31 receptor A.
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized |
Target | IL31RA |
Clinical data | |
Trade names | Nemluvio |
Other names | CIM-331, CD14152, nemolizumab-ilto |
AHFS/Drugs.com | Nemluvio |
License data |
|
Routes of administration | Subcutaneous injection |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Metabolism | Proteolytic enzymes |
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG |
Nemolizumab was invented by Chugai, who sold an exclusive license for the drug's development and worldwide marketing (except Japan and Taiwan) to Galderma in 2016.[3]
Nemolizumab was approved for medical use in the United States in August 2024.[4]
Medical uses
editNemolizumab is indicated for the treatment of adults with prurigo nodularis.
Society and culture
editNames
editNemolizumab is the international nonproprietary name.[5]
References
edit- ^ "Nemluvio- nemolizumab-ilto injection, powder, lyophilized, for solution". DailyMed. 13 August 2024. Retrieved 5 September 2024.
- ^ Spreitzer H (27 March 2017). "Neue Wirkstoffe - Nemolizumab". Österreichische Apothekerzeitung (in German) (7/2017).
- ^ "Chugai grants exclusive global license for development and marketing of nemolizumab to Galderma". Pharmabiz.com. 22 July 2016.
- ^ "Galderma Receives U.S. FDA Approval for Nemluvio (nemolizumab) for Adult Patients Living With Prurigo Nodularis" (Press release). Galderma. 13 August 2024. Retrieved 14 August 2024 – via Business Wire.
- ^ World Health Organization (2015). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 74". WHO Drug Information. 29 (3). hdl:10665/331070.
Further reading
edit- Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, et al. (October 2023). "Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis". The New England Journal of Medicine. 389 (17): 1579–1589. doi:10.1056/NEJMoa2301333. PMID 37888917.
External links
edit- Clinical trial number NCT04501666 for "Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)" at ClinicalTrials.gov
- Clinical trial number NCT04501679 for "A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)" at ClinicalTrials.gov